This was an observational cohort study of 336 consecutive patients with the diagnosis of ICM (≥70% stenosis in ≥1 epicardial coronary Background-Ischemic mitral regurgitation (IMR) is associated with poor outcomes. It is unknown what factors contribute to progression of IMR and how progressive IMR affects outcomes. We sought to determine imaging predictors of IMR progression and to determine if progressive IMR is an independent predictor of survival in patients with advanced ischemic cardiomyopathy. Methods and Results-Consecutive advanced ischemic cardiomyopathy patients who underwent cardiac magnetic resonance and echocardiograms at baseline with echocardiographic follow-up were studied. Cardiac magnetic resonance was used to assess left ventricular volumes, infarct size, and mitral valve geometry. The effective regurgitant orifice area (EROA) was calculated from the proximal isovelocity surface area by echocardiography. Repeated measures mixed effects and Cox proportional hazards regression models were built to identify predictors of IMR progression and survival. We evaluated 336 patients (age, 62±11 years) over a median follow-up time of 54 months: 154 patients were subsequently revascularized, and 182 patients were medically treated. Ninety-eight patients (29%) demonstrated an increase in EROA values of ≥0.1 cm 2 . There were 87 adverse events (death or transplant). On multivariable analysis, infarct size (P<0.001), progression in IMR (P=0.008), age (P=0.003), and baseline EROA (P=0.010) were independently associated with adverse events. Independent predictors of IMR progression were as follows: baseline EROA (P<0.001), left ventricular end-systolic volume index (P=0.014), and total scar (P=0.036). Conclusions-IMR frequently increases in severity, and progression is independently associated with adverse left ventricular remodeling and infarct size, as assessed by cardiac magnetic resonance. Furthermore, IMR progression is a powerful independent predictor of adverse events, even after controlling for the severity of IMR at baseline. (Circ Cardiovasc Imaging. 2016;9:e004577.
I schemic mitral regurgitation (IMR) as a result of myocardial infarction (MI) has been shown to be an extremely powerful independent predictor of heart failure and death. [1] [2] [3] [4] Although increasing IMR severity has been shown to be significantly associated with increasing mortality, 2 significant left ventricular (LV) dilation, systolic dysfunction, and myocardial scar burden likely contribute to the progression of IMR, and they have also been shown to be powerful imaging predictors of adverse events in patients with ischemic cardiomyopathy (ICM). [5] [6] [7] [8] [9] [10] IMR may become more severe with adverse remodeling during followup, and as a result, further adverse remodeling likely ensues. Therefore, we sought to determine the prognostic importance of LV remodeling, subsequent treatment, and IMR progression during follow-up, in patients with advanced ICM after adjusting for important imaging and clinical parameters. Predictors and Prognostic Impact of IMR Progression vessel on angiography or history of MI or coronary revascularization) 11 with LV systolic dysfunction (ejection fraction <50%), who were referred for clinically indicated myocardial viability assessment with cardiac magnetic resonance (CMR) between January 2002 and January 2013. Patients with standard CMR contraindications were not included. We identified 336 consecutive patients who had an echocardiogram at baseline (within 1 month before initial CMR) and at follow-up (at least 3 months after initial CMR) for inclusion in the study. Clinical variables were gathered prospectively through medical chart review. Medical treatment, post-CMR coronary revascularization (either percutaneous or surgical), and implantable cardioverter defibrillator/cardiac resynchronization therapy implantation were recorded. Assessment of the completeness of revascularization was determined based on the integration of coronary angiography anatomy, degree of myocardial scarring within these vascular territories on CMR, and subsequent revascularization in these corresponding vascular territories. Viable vascular territories were defined as areas with ≤50% transmural scarring based on delayed hyper enhance (DHE)-CMR assessment, according to the standard American Heart Association 16-segment model, with corresponding major epicardial coronary artery stenosis ≥70% stenosis. Vascular territories with >50% transmural scarring were considered nonviable. Viable vascular territories that were not subsequently revascularized were considered incompletely revascularized. 9 This study was approved by the Institutional Review Board, with a waiver of individual consent.
Clinical Outcomes
The primary combined end point was all-cause mortality and heart transplant. Death notification was confirmed by observation of death certificate or verified with a family member. The mean follow-up time was 4.5 years.
Echocardiographic Assessment
All patients underwent a comprehensive echocardiogram (Echo) with commercially available instruments (Philips Medical Systems, NA, Bothell, WA; General Electric Medical Systems, Milwaukee, WI; and Siemens Medical Solutions USA, Inc, Malvern, PA) as part of a standard clinical diagnostic evaluation at baseline and follow-up. Measurements and recordings were obtained according to the American Society of Echocardiography recommendations. 12 Severity of mitral regurgitation was assessed using the effective regurgitant orifice area (EROA), which was calculated from the proximal isovelocity surface area. The regurgitant volume was calculated by multiplying the time-velocity integral of the regurgitant flow with the calculated EROA. Significant progression of IMR was defined as an increase of ≥0.1 cm 2 EROA between baseline and follow-up echocardiography. Significant IMR was defined as ≥0.2 cm 2 EROA. 3
CMR Assessment
CMR studies were obtained on commercially available CMR scanners (Sonata/Avanto 1.5 T, Siemens Medical Solutions, Erlangen, Germany or Achieva 1.5-T XR/Ingenia 3.0-T; Philips Medical Systems, Best, The Netherlands) as previously described. 10 The median time difference between initial echocardiography and CMR was 3 days. For assessment of global cardiac function, steady state-free precession cine images were acquired (slice thickness of 8-10 mm in contiguous short-axis images). LV end-systolic (LVESV) and diastolic volumes and LV ejection fraction were calculated on short-axis cine images. LV shape was assessed by calculation of the sphericity index in diastole using the following formula: (D1+D2+D3)/3L, where L was measured in the 4-chamber view from the apex to the midpoint of the mitral valve, and D1 to D3 were measured as the axis that perpendicularly intersects tertile of the long axis. DHE-CMR images were obtained in longand short-axis orientations, ≈15 to 20 minutes after injection of 0.2 mmol/kg of gadolinium dimeglumine. DHE-CMR images were analyzed using commercially available software (cvi42; Circle Cardiovascular Imaging, Calgary, Alberta, Canada). 13 Endocardial and epicardial myocardial edges were manually delineated on DHE-CMR images. Scar was defined by intensity >2 SDs higher than user-defined viable myocardium. 14 Infarct heterogeneity was also quantified, and the peri-infarct area was defined as areas with signal intensity of 2 to 3 SDs higher than the user-defined myocardium. 15 The scar percentage was automatically determined as the percentage of total myocardium (infarct mass divided by total LV mass). Relative infarct burden within designated anterior, inferior, and lateral territories was calculated as the proportion of segmental scores contained within each territory, multiplied by global LV infarct size as previously described with the standard American Heart Association 16-segment model. Papillary muscle infarction was deemed present if any papillary hyperenhancement was evident on DHE-CMR short-axis images in accordance with established criteria. 16 Mitral geometric variables were measured in 3-chamber orientation during ventricular end systole. Mitral annular diameter was measured in a linear plane extending from the respective junctions of anterior and posterior valve leaflets with the atrial wall. Coaptation depth was defined as the distance between leaflet coaptation and the mitral annulus. Tenting area encompassed the area enclosed between the annulus and the mitral valve leaflets. Mitral regurgitant volume was calculated as the difference between the LV stroke volume (as determined by endocardial segmentation of cine images) and forward aortic flow by flow quantification obtained from the midascending aorta. The mitral regurgitant fraction was calculated by subtracting the forward aortic stroke volume from the LV stroke volume and dividing by the LV stroke volume.
Statistical Analysis
The goals of the analysis were to identify predictors of patient outcome and predictors of EROA change over time. Potential predictors of outcome were first assessed in univariate Cox proportional hazards models. Potential predictors were evaluated for proportional hazards assumption, linearity, and normality. The following independent variables were considered: treatment group (medical or revascularization or mitral valve surgery), age, sex, glomerular filtration rate (GFR), diabetes mellitus, hypertension, pre-CMR coronary artery bypass grafting or percutaneous coronary intervention, total scar percentage, per-infarct percentage, EROA at the time of the first echocardiogram, ESVi, and the difference in EROA on subsequent follow-up echocardiograms, according to previous survival studies. 3 Variables, not significant at the 0.20 level, were not considered in the multiple-variable analysis. Multiple-variable Cox proportional hazards regression models were then fit, including 2-way interactions with treatment. Interaction terms not significant at the 0.05 level were removed from the model.
Multiple-variable repeated measures mixed effects models were fit to test the effect of simultaneous predictors of change in EROA over time in a similar strategy to that used with the Cox proportional hazards regression models. Because the EROA measurements were positively skewed, a log transformation was used (ie, log [y+0.05]) based on the maximum likelihood estimate of the optimal power parameter of a Box-Cox transformation. PROC MIXED in SAS was used to handle the irregular spacing and variable number of follow-ups per patient. In the multiple-variable regression models, all 2-way interaction terms were considered. Interaction terms not significant at the 0.05 level were removed from the model.
Kruskal-Wallis test, Student t test, and χ 2 test were used to compare the baseline characteristics of the 2 groups of patients and to compare patients with 1 echo study versus follow-up echo studies. EROA for each patient were performed in a blinded manner by 3 independent observers. Each observer performed 2 independent measurements of EROA values on same echocardiographic images in a randomly selected 10 patients. Variability was measured in a 2-way analysis of variance model with calculation of intra-and interobserver SD (SEM intra and SEM inter ). SEM intra expresses the random error by a single observer, whereas SEM inter is an indicator of the mean variation between different observers. 17
Results

Study Population
We analyzed 336 patients: 154 were subsequently revascularized, and 182 were medically treated. Ninety-eight patients (29%) demonstrated an increase in EROA values of ≥0.1 cm 2 . There were 87 with adverse events (death or transplant). The median time between the baseline and follow-up echocardiography was 7 months. Baseline clinical variables, patient/ imaging characteristics based on treatment type, and IMR progression are listed in Table 1 . Our study cohort (n=336) was older (62±11 years) and predominantly male (80%) with a high prevalence of cardiovascular risk factors. A total of 44% had previous revascularization and a majority received optimal medical therapies including β-blockers, ACE inhibitor or angiotensin receptor blocker, and statin. The majority of patients in our study had EROA values of <0.2 cm 2 , (228 patients [68%]). There were 60 patients (18%) with EROA values of 0.2 to 0.3 cm 2 , and 47 patients (14%) with EROA values of >0.3 cm 2 . After CMR, 46% of patients underwent coronary revascularization with either coronary artery bypass grafting or percutaneous coronary intervention. In those who underwent coronary revascularization, 19% had 1 territory that was not completely revascularized because of poor target vessels. In those who were medically treated, 54% were not revascularized, as they were thought to be too high risk for coronary intervention. The prevalence of papillary muscle infarction was 19% in our study group, and 31% had subsequent ICD implantation.
Effect of Mitral Regurgitation Progression on Survival
Patient characteristics based on treatment type are outlined in Table 1 . The unadjusted hazard ratios obtained by Cox proportional hazards regression are shown in Table 2 Table 3 ). Among patients with EROA values of ≥0.20 at baseline, the hazard ratio was 1.8× higher than the patients with EROA values of <0.20 at baseline (P=0.010; Figure 1 ). Controlling for EROA value at baseline, patients with larger increases in EROA between the first and the second Echo had a higher hazard ratio: for each 0.1 cm 2 increase in EROA between the first and the second Echo, the hazard ratio increased by 20% (P=0.008; Figure 2 ).
Predictors of IMR Progression
We then sought to determine the predictors of IMR progression in our study population. The univariate analysis results are summarized in Table 4 . Older patients, and patients with lower GFR, higher ESV index, EROA values of >0.20 cm 2 at first Echo, incomplete revascularization, and more scar had higher EROA values. Higher mean tenting area and higher mean apical displacement were also associated with progressive IMR. Mean apical displacement and mean mitral valve annulus were not included in the multiple-variable model because they are highly correlated with mean tenting area, r=0.65 and r=0.57, respectively, and mean tenting area had a stronger relationship with EROA. Table 5 summarizes the final multiple-variable repeated measures regression model for EROA, which included the main effects from Table 4 and all statistically significant 2-way interactions with treatment. EROA values changed significantly over time (P<0.001), tending to decrease initially, and then rise over time. Patients with EROA values of ≥0.20 cm 2 on the baseline echocardiogram had higher EROA values over time (P<0.001). In addition, patients with higher total scar values developed more progressive IMR during followup (P=0.036; Figure 3 ). Patients with lower GFR also developed more progressive IMR. Higher LVESV index (LVESVi) values were predictive of higher EROA.
The interaction of treatment (revascularization versus medical treatment) and total scar was not a significant predictor of IMR progression (P=0.278). Furthermore, although incomplete revascularization was a univariate predictor of IMR progression, it was not a significant independent predictor of changes in EROA over time after controlling for LVESVi, renal function, and total scar burden (P=0.218). In addition, incomplete revascularization was not independently associated with IMR progression (P=0.175). Assessment of regional MI demonstrated that large anterior and inferior MIs were significantly associated with IMR progression on univariable analysis. However, anterior scar (P=0.733), lateral scar (P=0.816), and inferior scar (P=0.635) did not emerge as independent predictors of IMR progression, after controlling for LVESVi, renal function, and total scar burden. In addition, there was also no significant interaction between inferior scar and EROA at baseline (P=0.686). 
Observer Variability and Accuracy of Effective Regurgitant Orifice Area
The SEM intra was 0.02 cm 2 and the SEM inter was 0.04 cm 2 . The Figure I in the Data Supplement compares echocardiographic and CMR measurements of mitral regurgitant volume in ICM. Mitral regurgitant volume calculated by echocardiography and CMR were tightly correlated. CMR slightly underestimated volumes (bias: −12.5 mL); the bias was more pronounced in the setting of larger regurgitant volumes.
Discussion
Our study sought to determine the mechanisms and prognostic importance of IMR progression in patients with advanced ICM using a multimodality assessment of LV remodeling, Survival based on ischemic mitral regurgitation (IMR) progression. Survival analysis depicting the difference in survival based on baseline effective regurgitant orifice area (EROA) value and change in EROA between the first and the second Echo: patients with baseline EROA values of <0.2 cm 2 whose EROA stayed the same or decreased by the second Echo (blue) vs patients with baseline EROA values of <0.2 cm 2 whose EROA increased by the second Echo (purple) vs patients with baseline EROA values of ≥0.2 cm 2 whose EROA stayed the same or decreased by the second Echo (red) vs patients with baseline EROA values of ≥0.2 cm 2 whose EROA increased by the second Echo (orange). For both baseline EROA groups, patients with increases in EROA between the first and the second Echo had a higher hazard ratio. There were 155 patients with baseline EROA values of <0.20 cm 2 whose EROA stayed the same or decreased by the second Echo, including 25 failures. There were 65 patients with baseline EROA values of <0.20 cm 2 whose EROA increased by the second Echo, including 19 failures. There were 83 patients with EROA values of ≥0.20 cm 2 whose EROA stayed the same or decreased by the second Echo, including 26 failures. There were 33 patients with EROA values of ≥0.20 cm 2 whose EROA increased by the second Echo, including 17 failures. Predictors and Prognostic Impact of IMR Progression myocardial infarct size and location, and mitral valve geometry. Significant IMR progression occurred in ≈18% of patients over a median follow-up time of 7 months. Our study brings several new insights into the understanding of IMR in patients with chronic advanced ICM: (1) progressive IMR is a powerful independent predictor of poor survival, even after controlling for severity of baseline IMR severity; (2) IMR progression was significantly and independently associated with more advanced LV dilation, more extensive MI, and higher baseline IMR severity; (3) although mitral valve geometry and infarct location are strong univariate predictors of mitral valve progression, these variables were no longer significant predictors on multivariable analysis, after controlling for baseline mitral regurgitation severity, extent of LV dilation, and total infarct size assessed by DHE-CMR.
Predictors of IMR Progression in ICM
Our findings bring several new facets to light in further understanding the complex interplay between the extent of myocardial scarring, LV remodeling, mitral valve geometry, and subsequent progression of IMR. There is much controversy findings in the literature in regard to the precise mechanisms of IMR. Classically, significant ventricular remodeling and resultant apical displacement of the papillary muscles are thought to be the main contributors to IMR. [18] [19] [20] Previous studies have demonstrated that posterior wall infarction, papillary muscle infarction, and ventricular dilation are requirements for the development of IMR 16, [21] [22] [23] ; however, these studies were in the setting of single-vessel infarcts with less adverse LV remodeling and dysfunction. In addition, infarct size was not assessed in these previous studies. Therefore, it is not clear how extensive multivessel MIs with resultant severe LV dysfunction, may affect the evolution and progression of IMR. In our study, although the majority of patients had severe LV dysfunction (mean LV ejection fraction, 27%), only 32% of our study patients had significant IMR (EROA >0.2 cm 2 ), with only 14% of patients with EROA values of >0.3 cm 2 . Although papillary muscle function has been implicated as an important contributor to IMR, 24, 25 papillary muscle infarct was not a significant predictor of ischemic mitral regurgitation in recent study by Chinitz et al. 16 Similarly, papillary muscle infarction was not found to be significant predictor of IMR progression in our study.
Mitral valve geometry has been shown to be significantly altered in patients with IMR and ICM. 22, [26] [27] [28] [29] Increased mitral valve tenting area and apical displacement were found to be strong univariate predictors of EROA progression in our study. However, abnormal mitral valve geometry did not emerge as an independent predictor of IMR progression on our multivariable analysis. This is probably because of the fact that baseline IMR severity was included in the multivariable model. Baseline EROA was the strongest predictor of IMR progression in our multivariable model. Thus, the more severe the IMR at baseline, the more likely the IMR will continue to progress over time. Although abnormal IMR at baseline is probably, in large part, because of abnormal mitral geometry, the current literature demonstrates the complexity of the mechanisms of IMR with numerous variable contributing factors. Therefore, abnormal mitral geometry in isolation did not emerge as an independent predictor of IMR progression when controlling for EROA severity at baseline probably because of its extremely significant independent prediction of IMR severity at baseline.
Previous studies have suggested that IMR can significantly improve with revascularization. 30, 31 However, revascularization did not emerge as an independent predictor of IMR progression after adjusting for LV size, EROA at baseline, and total myocardial scar burden. Similarly, Aklog et al 32 demonstrated the limited impact of coronary artery bypass grafting in patients with chronic IMR. Because several of the medically treated patients could not undergo revascularization and they were thought to be too high risk, we evaluated the impact of the presence of incomplete revascularization on the progression of IMR. Although incomplete revascularization was a significant univariate predictor of IMR progression, it lost its significance after controlling for EROA at baseline, LV size, and total infarct size, which were much more powerful predictors of IMR progression.
Predictors of Mortality in ICM
Although baseline IMR has previously been shown to be a powerful predictor of mortality, 2 the impact of IMR progression after controlling for baseline IMR severity, adverse LV remodeling, and myocardial infarct size has not previously been extensively investigated. We found that IMR progression was a powerful independent predictor of poor outcomes, event after controlling for baseline IMR severity, age, and infarct size. In our study, patients with EROA values of ≥0.20 cm 2 at baseline had 1.8× higher risk of mortality or heart transplant than patients with EROA values of <0.20 cm 2 at baseline (P=0.010; Figure 1 ). However, IMR progression added further risk stratification. Even after controlling for EROA values at baseline, for each 0.1 cm 2 increase in EROA between the baseline echo and follow-up echocardiograms, the hazard ratio increased by 20% (P=0.008; Figure 2 ). The significance of an increase in EROA values of 0.1 cm 2 has also been previously shown in 2 studies demonstrating incremental risk stratification in patients who experienced an increase in EROA values of 0.13 cm 2 with exercise. [33] [34] [35] Our study also demonstrated the independent prognostic power of older age, total infarct size, and diabetes mellitus. The results of this study are consistent with the previous work demonstrating the prognostic power of age, total scar %, LV size, and GFR 36 in predicting adverse outcomes in patients with chronic MI. We have previously shown that age, EROA at baseline, total scar %, and renal function are significantly and independently related to mortality in patients with chronic ICM. 10, 37 This study demonstrates the important prognostic value of IMR progression after controlling for these well-established predictors of mortality. Although we have previously demonstrated that patients with increased LVESVi experienced significantly improved survival after revascularization, 10 revascularization did not affect survival when IMR progression was taken into account. Furthermore, IMR progression provides further risk stratification in patients who have significant IMR at baseline. Those with severe IMR but no significant IMR progression over time demonstrated significantly improved survival compared with patients with severe IMR and continued progressive IMR. This finding further illustrates the prognostic importance of IMR progression, and the need to develop effective treatment strategies for minimizing or preventing further IMR progression.
Clinical Implication
Numerous studies have demonstrated the extremely complex nature of IMR, with various interactions of ischemia, infarct, and resultant geometric derangements of the ventricle and mitral valve geometry. Our study is the first to demonstrate the prognostic significance of IMR progression in patients who underwent medical treatment versus revascularization. In addition, our study demonstrates the importance of baseline IMR severity, LV size, and infarct size in predicting further IMR progression over time.
Although chronic IMR is a common finding after MI and is highly predictive of heart failure and death, there is limited data on the impact of progression of IMR on survival. In this study, we demonstrated that IMR progression is a powerful predictor of all-cause mortality in patients with advanced ICM, independent of age, sex, LV size, and total scar burden. Knowledge of the myocardial scar burden may be important in deciding which patients with moderate mitral regurgitation should undergo mitral valve intervention among patients who are being referred for surgical revascularization. Further studies are needed to determine if there is differential benefit in revascularization±mitral valve intervention in patients based on the severity of myocardial scar and adverse LV remodeling, assessed by cardiac magnetic resonance imaging.
Multimodality imaging can provide comprehensive assessment of IMR, adverse LV remodeling, and infarct size, which can help predict which patients are at highest risk for increasing severity of IMR. Because increasing IMR is associated with adverse events, comprehensive multimodality imaging may provide an important assessment in determining appropriate therapy.
Limitations
This was a retrospective, nonrandomized, single-center study that included a selected population of patients with MI and only included those who could undergo DHE-CMR study and that returned for follow-up echocardiographic studies within our institution. In addition, patients who underwent mitral valve repair or replacement after the baseline CMR were also excluded, as this intervention acutely decreased the severity of IMR in the early follow-up period. Patients with previous device implantation were excluded from this study because of the contraindications for CMR; therefore, significant selection bias may be present.
Calculating EROA with the proximal isovelocity surface area method may underestimate the severity of IMR due geometric assumptions of an assumed hemisphere. 38, 39 However, the degree of underestimation seems to be consistent in our study, as we demonstrated a strong correlation (r=0.79, P<0.001) between EROA measured on the baseline echocardiogram and the regurgitant fraction by the baseline cardiac magnetic resonance imaging. Because quantification of IMR with the proximal isovelocity surface area method is load dependent, variations in blood pressure can significantly affect EROA measurements. However, many patients in our study had several follow-up echocardiograms throughout the follow-up time, and EROA was calculated on all of the follow-up echocardiograms and incorporated in our analysis. Therefore, we think that our data are more robust and less likely to be a result of increased IMR because of isolated events of uncontrolled blood pressure.
Although our primary end point included only all-cause mortality and heart transplant, we feel that this captures unequivocal hard end points. We think that majority of deaths are likely cardiac related, given the advanced nature of the ICM in our patient population. Furthermore, because there were only a small number of cardiac transplants, there is little to be gained to model mortality and transplant separately.
We feel that the findings of this study reveal important insights into the mechanisms and prognostic power of progressive mitral regurgitation in patients who are medically treated versus revascularized in the follow-up period. Further studies are needed to determine whether patients who are at highest risk for progressive IMR would benefit from mitral valve intervention versus device therapy.
Conclusions
Our study demonstrates that IMR frequently increases in severity, and progression is independently associated with adverse LV remodeling and infarct size, as assessed by CMR. Furthermore, IMR progression is a powerful independent predictor of adverse events in advanced ICM, even after controlling for the severity of IMR at baseline. In addition, EROA at baseline, age, total scar %, and renal function also emerged as important risk factors in this population. LV remodeling and IMR assessment during follow-up provides incremental prognostic value to the baseline clinical characteristics and CMR data, thus resulting in improved risk stratification.
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